IIT-I to develop tech translation research park
Indore: Indian Institute of Technology, Indore (IIT-I), is developing a
Technology Translation Research Park
(TTRP) with an aim to enhance digital health solutions and creating a seamless digital health ecosystem in the country.
The advanced facility at IIT-I in
digital healthcare
to be set up under the National Mission on Interdisciplinary Cyber-Physical Systems (NM-ICPS) will work to bridge the gap between urban and rural healthcare services, leveraging
telemedicine
,
electronic health records
(EHRs), artificial intelligence-driven diagnostics and personalised medicine and care.
The institute received a nod from the department of science and technology and governing body of NMICPS led by Kris Gopalakrishnan, founder of Infosys, to upgrade IIT-I's technology innovation hub
Drishti CPS Foundation
into a TTRP with an outlay of Rs 250 crore for next three years in tranches. Of the total proposed amount Rs 52 crore has been received by the foundation.
"The new TTRP comes as a great validation of the initiatives on digital healthcare that has been incubated in IIT-I. We look forward to extending the mandate of IIT-I Drishti CPS Foundation into the digital healthcare through this new TTRP," said IIT-I director professor Suhas S Joshi.
IIT-Indore established the Drishti CPS Foundation in 2020, which has so far supported over 150 technology projects and startups with funds and mentoring.
Drishti CPS Foundation CEO Aditya Vyas said, "The research park will cater to the growing need of the nation in creating a robust digital health infrastructure. Drishti CPS is developing a flagship unified human digital twin platform - CharakDT.
The novel, systematic and scalable architecture of CharakDT allows a unique way of creating individual health models (twins) for each patient by aggregating contextual data from multifarious sources and implementing large-scale AI models across dimensions of organ physics, demography, diagnostic tools, and environment."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
19 minutes ago
- Time of India
UP inks Rs 435cr MoUs at Ahmd roadshow
Lucknow: Inviting pharma sector players to come and invest in UP during a roadshow in Ahmedabad on Friday, CEO of UP state industrial development authority (UPSIDA), Mayur Maheshwari said that a new era for the pharma sector is taking place in UP. "UP is developing a bulk drug pharma park on 1,472.33 acre in Lalitpur, with a proposed investment of approximately Rs250 crore. This project is a significant step towards making the country self-reliant in the pharmaceutical sector and establishing India as the 'Pharmacy of the world'," he said, adding, "it will not only attract substantial investment but also create new employment opportunities for the skilled workforce in the state. " Several agreements were signed by UPSIDA with pharma companies on the occasion. The list includes CSL Lifesciences Private Limited, which proposed an investment of Rs 200 crore for establishing an intravenous bottle plant and oral solid dosage plant within the next two years. Likewise, Medihealth Diagnostic Pvt Ltd will establish a healthcare unit on 4,200 sqmt in Lalitpur, while Gaman Irradiation Company will invest Rs 35 crore in a skin treatment and irradiation unit. Creating employment for 150 people, the project will be implemented in 24-36 months. Additionally, Obmed Pharma has decided to invest Rs 200 crore to establish a formulation unit. Spread across five acre of land in Lalitpur, the unit will create employment for around 100 people. Several business-to-govt meetings were held, where detailed discussions on investment-related topics took place between industry representatives and govt officials. Earlier, in the welcome address, convenor of CII Gujarat pharma and healthcare panel, Swapnil Shah highlighted investment opportunities in UP. Advisor to UP CM, GN Singh said, "UP emerged as the most suitable state for investment in the pharma sector". He shared detailed information about the efforts made by the state govt to empower the pharma sector. An 'Open House' session followed, where participants engaged in direct dialogue with state govt officials to resolve their queries and concerns. The programme concluded with a vote of thanks by chairman of Shalby Ltd, Shanay Shah. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !
News18
19 minutes ago
- News18
IIT Guwahati Researchers Use Clay-Based Method To 'Sculpt' Affordable Covid Testing Process
Last Updated: The IIT Guwahati team meticulously investigated how bentonite clay interacts specifically with SARS-CoV-2 Researchers at the Indian Institute of Technology (IIT) Guwahati have developed an innovative and cost-effective method for detecting SARS-CoV-2, the virus responsible for Covid-19. This novel technique uses a combination of bentonite clay and saltwater, offering a simpler and more affordable alternative to conventional diagnostic tools such as PCR and antigen tests. Their findings, published in the peer-reviewed journal Applied Clay Science, have the potential to revolutionise virus detection, particularly in resource-constrained settings and for future pandemic preparedness. This groundbreaking method hinges on the principle of sedimentation. Bentonite clay is renowned for its exceptional absorbent properties and its capacity to bind with various substances, including heavy metals and pollutants. Building on previous research suggesting that clay particles could interact with viruses, the IIT Guwahati team meticulously investigated how bentonite clay interacts specifically with SARS-CoV-2. Their research revealed that when the virus is present in a neutral pH saltwater solution at room temperature, it binds effectively with the clay particles. This binding accelerates sedimentation, with virus-laden clay particles settling more rapidly. By observing and measuring this accelerated sedimentation, researchers can accurately determine both the presence and concentration of the virus in a sample. The implications of this discovery are substantial, say some experts. While PCR tests are highly accurate, they are costly, require specialised equipment and trained personnel, and often depend on significant infrastructure, limiting their accessibility in remote or under-resourced areas. Antigen tests, while faster, can be less sensitive than PCR. In contrast, the IIT Guwahati method requires minimal equipment, is inherently affordable, and offers a potentially rapid diagnostic solution suitable for widespread deployment. First Published: June 07, 2025, 04:03 IST
Time of India
2 hours ago
- Time of India
Navy set to induct 1st of 16 desi shallow water craft on June 18
NEW DELHI: The Navy is now set to commission the first of the 16 specialised small warships, designed for anti-submarine warfare and low-intensity maritime operations along the coast, being built at Indian shipyards at an overall cost of Rs 12,622 crore. The first anti-submarine warfare shallow water craft, built by Kolkata-based defence shipyard Garden Reach Shipbuilders & Engineers (GRSE) in collaboration with L&T Shipbuilders, will be commissioned as INS Arnala at Visakhapatnam in the presence of chief of defence staff General Anil Chauhan on June 18. The 77-metre-long craft, with a displacement of 1,490 tonne and equipped with state-of-the-art underwater sensors, is the largest Indian warship till now to be propelled by a diesel engine-waterjet combination. "The warship incorporates over 80% indigenous content and integrates advanced systems from leading Indian defence firms, including Bharat Electronics Limited, L&T and Mahindra Defence," an officer said. GRSE and Cochin Shipyard are each building eight of these warships under twin Rs 6,311 crore contracts inked with them in April 2019. All the warships are supposed to be delivered by 2028. Named after the historic Arnala Fort off Vasai in Maharashtra, the first of these 16 warships reflects India's rich maritime heritage.
